Celcuity (CELC) stock price is $61.19, up 1.98% on the day, as of Oct 21, 2026. It has a market cap of $3.36Bn, and is classified in the Biotechnology industry (Healthcare sector).
Enterprise Value
Margins
P/FCF
Key Stats
Market Cap3.36 Bn
P/E-15.33
Div. Yield0.00
Add ratio to table…
About
Celcuity Inc. is a clinical stage biotechnology company focused on the development of targeted therapies for solid tumor indications. Its lead therapeutic candidate is gedatolisib a pan class I inhibitor of phosphatidylinositol 3 kinase protein kinase B and mechanistic target of rapamycin that simultaneously targets all class I PI3K isoforms and both mTORC1 and mTORC2 complexes. By blocking the entire phosphatidylinositol 3 kinase AKT mechanistic target of rapamycin pathway…
Celcuity Inc. is a clinical stage biotechnology company focused on the development of targeted therapies for solid tumor indications. Its lead therapeutic candidate is gedatolisib a pan class I inhibitor of phosphatidylinositol 3 kinase protein kinase B and mechanistic target of rapamycin that simultaneously targets all class I PI3K isoforms and both mTORC1 and mTORC2 complexes. By blocking the entire phosphatidylinositol 3 kinase AKT mechanistic target of rapamycin pathway gedatolisib aims to overcome resistance mechanisms seen with inhibitors that act on only one node of the pathway. The company is advancing gedatolisib through multiple clinical trials in breast cancer and prostate cancer. These trials evaluate gedatolisib both as a single agent and in combination with established hormonal therapies and cyclin dependent kinase inhibitors. Celcuity operates in the oncology biotechnology sector with a mission to deliver novel treatments that address unmet medical needs.
Celcuity Inc. does not currently generate product revenue because gedatolisib remains an investigational drug. The company finances its operations through equity offerings and the upfront payment received from its license agreement with Pfizer. Under that agreement Celcuity may receive milestone payments upon regulatory and commercial achievements and will owe tiered royalties on future net sales of gedatolisib if it gains approval. Additional funding sources include government grants and collaboration agreements that support preclinical and clinical research activities. The firm also pursues potential partnership deals that could provide further financial resources and shared development costs. Should gedatolisib achieve regulatory approval Celcuity anticipates revenue from product sales royalties and milestone payments from collaborators.
Within the competitive landscape of phosphatidylinositol 3 kinase AKT mechanistic target of rapamycin pathway inhibitors Celcuity Inc. differentiates itself through the broad activity of gedatolisib against all class I PI3K isoforms and both mTORC1 and mTORC2 complexes. Several approved agents such as alpelisib from Novartis capivasertib from AstraZeneca everolimus from various manufacturers and idelalisib from Gilead target only single nodes of the pathway. Celcuity believes that the intravenous administration schedule of gedatolisib and its favorable safety profile provide advantages over oral pan class I inhibitors that have faced dose limiting toxicities. The firm has obtained Fast Track designation and Breakthrough Therapy designation from the US Food and Drug Administration for the hormone receptor positive HER2 negative advanced breast cancer indication after progression on cyclin dependent kinase 4 6 therapy highlighting the perceived clinical promise of its candidate. Intellectual property protection is a key component of Celcuity's strategy with exclusive worldwide rights to gedatolisib obtained through a license agreement with Pfizer covering numerous issued patents in the United States and abroad. The company also files its own patent applications covering novel formulations and methods of use to extend market exclusivity beyond the term of licensed patents. Market analysts estimate that if gedatolisib gains approval for both PIK3CA wild type and mutant populations in hormone receptor positive HER2 negative advanced breast cancer the peak annual sales could reach several billion dollars reflecting the large unmet need in this patient segment. Competitors include large pharmaceutical companies with extensive resources as well as smaller biotech firms that are pursuing similar pathway inhibition strategies.
As a pre revenue company Celcuity Inc. serves clinical trial sites investigators and study participants in its ongoing research programs. Upon potential approval its customers would include hospitals oncology clinics and physicians who treat patients with advanced breast cancer prostate cancer and other solid tumor indications. The company also anticipates interactions with health insurance providers and government payers that determine coverage and reimbursement for its future therapies. Academic medical centers and community oncology practices are expected to be key sites for administering gedatolisib if it receives marketing authorization. While the filing does not disclose specific customer names Celcuity has established relationships with numerous research institutions and clinical trial networks to support its development programs. These collaborations facilitate patient enrollment data collection and regulatory submission processes essential for advancing gedatolisib toward potential commercialization.
Sector:HealthcareSector rationaleCelcuity is a clinical-stage biotechnology company developing gedatolisib, a targeted therapy for solid tumors such as breast and prostate cancer. Its core business activity is the discovery and development of pharmaceuticals, which falls squarely within the Biotechnology and Pharmaceuticals industries of the Healthcare sector.Industry:BiotechnologyBiotechnologyPrimaryCelcuity is a clinical-stage biotechnology company developing gedatolisib, a targeted therapy for solid tumors. Its revenue model currently relies on collaboration payments and milestones from partners like Pfizer, which is characteristic of biology-based drug discovery and development.Classified using BQ-MICSCIK: 0001603454
Bull & bear
Investment Thesis
▲ Bull case
Celcuity's strategic expansion of VICTORIA-2 into both endocrine-sensitive and endocrine-resistant first-line settings represents a significant de-risking of its commercial outlook, as it positions gedatolisib to capture nearly the entire newly diagnosed HR+/HER2- advanced breast cancer population in the U.S., estimated at 90,000 patients annually. By decoupling primary efficacy endpoints from PIK3CA status and allowing enrollment based solely on endocrine sensitivity, the company has created a pathway to label expansion that does not rely on biomarker stratification, which could accelerate adoption and reduce commercial complexity. The FDA's alignment via a Type B meeting further validates this approach, suggesting regulatory confidence in the trial design despite the ambitious timeline to 2030 for topline data in Study 2. This dual-track first-line strategy transforms what was initially a second-line opportunity into a potential franchise asset, with the subcutaneous formulation development indicating long-term lifecycle management intent that could sustain market leadership beyond initial patent expiry.
The company's commercial readiness is substantially ahead of expectations, with a fully hired and experienced oncology sales force averaging 24 years in pharmaceutical sales and 16 years in oncology—metrics that far exceed industry benchmarks for launch readiness in oncology. This depth of experience, combined with ongoing payer and health system outreach, suggests Celcuity is not merely building infrastructure but actively shaping market access and formulary positioning well in advance of a potential FDA decision. The internal TAM estimate of over $5 billion annually for second-line use, coupled with a conservative peak revenue projection of $2.5 billion, implies significant pricing power and market share assumptions that are not fully reflected in current valuations, especially given the lack of direct PI3K/AKT/mTOR pathway inhibitors with comparable efficacy data in later-line settings.
Despite the Reuters-reported underperformance of the gedatolisib triplet in the PIK3CA mutant cohort versus early-stage trials, the context provided by management—specifically that one-third of early-stage patients were CDK inhibitor-naïve—reveals a critical nuance: the late-stage trial enrolled a heavily pretreated population with prior CDK4/6 inhibitor exposure, which is biologically more resistant to further pathway inhibition. The 11.1-month PFS improvement over Faslodex plus Piqray in this heavily pretreated cohort remains clinically meaningful and statistically significant, particularly when contrasted with historical benchmarks where CDK4/6 inhibitor resistance typically leaves few effective options. Furthermore, the doublet regimen's positive secondary endpoint and the wild-type cohort's unprecedented efficacy (7.3-month median PFS improvement over fulvestrant) suggest that gedatolisib's mechanism may be particularly effective in tumors without primary PIK3CA driver mutations, broadening its potential utility beyond the mutant population.
Celcuity's strategic expansion of VICTORIA-2 into both endocrine-sensitive and endocrine-resistant first-line settings represents a significant de-risking of its commercial outlook, as it positions gedatolisib to capture nearly the entire newly diagnosed HR+/HER2- advanced breast cancer population in the U.S., estimated at 90,000 patients annually. By decoupling primary efficacy endpoints from PIK3CA status and allowing enrollment based solely on endocrine sensitivity, the company has created a pathway to label expansion that does not rely on biomarker stratification, which could accelerate adoption and reduce commercial complexity. The FDA's alignment via a Type B meeting further validates this approach, suggesting regulatory confidence in the trial design despite the ambitious timeline to 2030 for topline data in Study 2. This dual-track first-line strategy transforms what was initially a second-line opportunity into a potential franchise asset, with the subcutaneous formulation development indicating long-term lifecycle management intent that could sustain market leadership beyond initial patent expiry.
The company's commercial readiness is substantially ahead of expectations, with a fully hired and experienced oncology sales force averaging 24 years in pharmaceutical sales and 16 years in oncology—metrics that far exceed industry benchmarks for launch readiness in oncology. This depth of experience, combined with ongoing payer and health system outreach, suggests Celcuity is not merely building infrastructure but actively shaping market access and formulary positioning well in advance of a potential FDA decision. The internal TAM estimate of over $5 billion annually for second-line use, coupled with a conservative peak revenue projection of $2.5 billion, implies significant pricing power and market share assumptions that are not fully reflected in current valuations, especially given the lack of direct PI3K/AKT/mTOR pathway inhibitors with comparable efficacy data in later-line settings.
Despite the Reuters-reported underperformance of the gedatolisib triplet in the PIK3CA mutant cohort versus early-stage trials, the context provided by management—specifically that one-third of early-stage patients were CDK inhibitor-naïve—reveals a critical nuance: the late-stage trial enrolled a heavily pretreated population with prior CDK4/6 inhibitor exposure, which is biologically more resistant to further pathway inhibition. The 11.1-month PFS improvement over Faslodex plus Piqray in this heavily pretreated cohort remains clinically meaningful and statistically significant, particularly when contrasted with historical benchmarks where CDK4/6 inhibitor resistance typically leaves few effective options. Furthermore, the doublet regimen's positive secondary endpoint and the wild-type cohort's unprecedented efficacy (7.3-month median PFS improvement over fulvestrant) suggest that gedatolisib's mechanism may be particularly effective in tumors without primary PIK3CA driver mutations, broadening its potential utility beyond the mutant population.
Celcuity's cash runway, while stated to extend through 2027, is increasingly strained by rising operating costs, with Q1 2026 net cash used in operating activities increasing by $19.2 million year-over-year to $55.1 million, driven largely by an $11.1 million surge in SG&A tied to commercial headcount additions and launch preparations. This burn rate implies that even with the current $290.4 million in cash and investments, the company may require additional financing before achieving potential FDA approval and initial commercial launch in Q3 2026, especially if approval is delayed beyond current expectations. The reliance on non-GAAP metrics to present a less severe loss picture ($46.8 million adjusted net loss vs. $52.8 million GAAP) raises concerns about the sustainability of current spending levels without near-term revenue, particularly as R&D costs remain elevated despite reduced VICTORIA-1 trial expenses.
The FDA's upcoming decision on July 17 regarding gedatolisib's use in advanced breast cancer patients without a PIK3CA mutation introduces significant binary risk, as a negative or delayed ruling could undermine the core rationale for the VICTORIA-2 expansion into first-line endocrine-sensitive patients, which assumes broad applicability regardless of mutation status. If the drug fails to demonstrate sufficient benefit in the wild-type population at label, the entire first-line strategy—including the planned subcutaneous formulation and patent pursuit—could lose strategic justification, rendering the $37 thousand patient endocrine-sensitive subgroup (2/3 of 90k annual diagnoses) inaccessible without further costly trials. This regulatory dependency creates a material overhang that is not adequately reflected in management's optimistic timelines for label expansion.
Although Celcuity projects peak second-line revenues of up to $2.5 billion annually, this assumption hinges on capturing a substantial share of the 37,000 U.S. patients receiving second-line HR+/HER2- treatment, implying aggressive pricing and market penetration that may be unattainable given the entrenched dominance of CDK4/6 inhibitor-based regimens and the emergence of competing PI3K-alpha inhibitors like Truqap (capivasertib) with established reimbursement pathways. The company's internal pricing assumptions, while consistent with novel therapeutics, do not account for potential payer resistance to premium pricing in a setting where efficacy gains—while statistically significant—may be viewed as incremental by formulary committees, especially when weighed against the added complexity of triplet therapy administration and subcutaneous formulation uncertainty.
Celcuity's cash runway, while stated to extend through 2027, is increasingly strained by rising operating costs, with Q1 2026 net cash used in operating activities increasing by $19.2 million year-over-year to $55.1 million, driven largely by an $11.1 million surge in SG&A tied to commercial headcount additions and launch preparations. This burn rate implies that even with the current $290.4 million in cash and investments, the company may require additional financing before achieving potential FDA approval and initial commercial launch in Q3 2026, especially if approval is delayed beyond current expectations. The reliance on non-GAAP metrics to present a less severe loss picture ($46.8 million adjusted net loss vs. $52.8 million GAAP) raises concerns about the sustainability of current spending levels without near-term revenue, particularly as R&D costs remain elevated despite reduced VICTORIA-1 trial expenses.
The FDA's upcoming decision on July 17 regarding gedatolisib's use in advanced breast cancer patients without a PIK3CA mutation introduces significant binary risk, as a negative or delayed ruling could undermine the core rationale for the VICTORIA-2 expansion into first-line endocrine-sensitive patients, which assumes broad applicability regardless of mutation status. If the drug fails to demonstrate sufficient benefit in the wild-type population at label, the entire first-line strategy—including the planned subcutaneous formulation and patent pursuit—could lose strategic justification, rendering the $37 thousand patient endocrine-sensitive subgroup (2/3 of 90k annual diagnoses) inaccessible without further costly trials. This regulatory dependency creates a material overhang that is not adequately reflected in management's optimistic timelines for label expansion.
Although Celcuity projects peak second-line revenues of up to $2.5 billion annually, this assumption hinges on capturing a substantial share of the 37,000 U.S. patients receiving second-line HR+/HER2- treatment, implying aggressive pricing and market penetration that may be unattainable given the entrenched dominance of CDK4/6 inhibitor-based regimens and the emergence of competing PI3K-alpha inhibitors like Truqap (capivasertib) with established reimbursement pathways. The company's internal pricing assumptions, while consistent with novel therapeutics, do not account for potential payer resistance to premium pricing in a setting where efficacy gains—while statistically significant—may be viewed as incremental by formulary committees, especially when weighed against the added complexity of triplet therapy administration and subcutaneous formulation uncertainty.